Results 171 to 180 of about 108,375,652 (210)
Some of the next articles are maybe not open access.
Tradipitant: A Novel Neurokinin-1 Receptor Antagonist for Motion Sickness
American Journal of TherapeuticsBackground: Motion sickness affects millions of people with common symptoms, including nausea and vomiting. Medications used for management of motion sickness since 1870 predominately have anticholinergics and antihistamines properties. For the past 40 years, there have been no advances in medication options for
Timothy, Nguyen +5 more
openaire +2 more sources
The Role of Neurokinin-1 Receptor Antagonists in CINV
2016Significant advances have been made in controlling chemotherapy-induced nausea and vomiting (CINV) in the past two decades. These advances are primarily due to a greater understanding of the physiological and molecular pathways underlying CINV, which resulted in major progress in the management of patients with CINV.
openaire +1 more source
Current Opinion in Anaesthesiology, 2008
To review the characteristics of neurokinin-1 receptor antagonists and their potential role in the management of postoperative nausea and vomiting.Neurokinin-1 antagonists compete with substance P, an endogenous ligand with a high density of receptors in the area postrema and the nucleus tractus solitarii, believed to be involved in terminal emetic ...
Christian C, Apfel +2 more
openaire +2 more sources
To review the characteristics of neurokinin-1 receptor antagonists and their potential role in the management of postoperative nausea and vomiting.Neurokinin-1 antagonists compete with substance P, an endogenous ligand with a high density of receptors in the area postrema and the nucleus tractus solitarii, believed to be involved in terminal emetic ...
Christian C, Apfel +2 more
openaire +2 more sources
Neurokinin-1 receptor antagonists modulate brain noradrenaline and serotonin interactions
European Journal of Pharmacology, 2008Substance P (neurokinin-1; NK1) receptor antagonists represent a putative new class of antidepressant/anxiolytic drugs. Using in vivo electrophysiological paradigms in rats, this study examined the effects of acute, sub-acute and long-term administration of these drugs on the firing of rat noradrenaline and serotonin (5-HT) neurons.
Nasser, Haddjeri, Pierre, Blier
openaire +2 more sources
Neurokinin-1-Receptor Antagonists: A New Approach in Antiemetic Therapy
Oncology Research and Treatment, 2006Aprepitant (Emend), the first neurokinin-1-receptor antagonist (NK-1-RA), represents a new class of antiemetics. Aprepitant has been approved for the prevention and treatment of acute (0-24 h after chemotherapy) and delayed (1-5 days after chemotherapy) emesis resulting from cisplatin-based chemotherapy and moderately emetogenic chemotherapy.
openaire +2 more sources
Neurokinin 1 receptor antagonists--current prospects.
Current opinion in drug discovery & development, 2007The isolation of substance P (SP) in 1931, and the later discovery of its preferred neurokinin (NK)1 receptor, led to an intense research effort aimed at elucidating the biological role of SP, particularly within the central nervous system. There is now a large body of evidence to support the hypothesis that SP is one of the most important ...
Giuseppe, Alvaro, Romano, Di Fabio
openaire +1 more source
Spiro-piperidine non-peptide neurokinin-1 receptor antagonists
Bioorganic & Medicinal Chemistry Letters, 1995Abstract The synthesis and activity of a novel spiro-piperidine non-peptide antagonist (2) of the neurokinin-1 (NK 1 ) receptor is described. Despite having essentially the same solution conformation as CP 99,994 (1) at physiological pH, (2) has reduced affinity for the NK 1 receptor.
D.R. Armour +12 more
openaire +1 more source
[Neurokinin 1 receptor antagonists--between hope and disappointment].
Medizinische Monatsschrift fur Pharmazeuten, 2006Substance P (SP)/Neurokinin 1 (NK1) receptor pathways have been repeatedly implicated in the pathophysiology of central, pulmonary, and gastric disorders. A large body of evidence that has been generated from animal experiments indicates that treatment with selective NK1 receptor antagonists might be effective in the treatment of certain forms of ...
Kristin, Rost +2 more
openaire +1 more source
Neurokinin Receptor Antagonist, Fezolinetant, for Treatment of Menopausal Vasomotor Symptoms
Journal of Clinical Endocrinology and Metabolism, 2023Joann V Pinkerton, Andrew M Kaunitz
exaly
Recent Advances in Neurokinin-3 Receptor Antagonists
Expert Opinion on Therapeutic Patents, 2000Luca F Raveglia
exaly